XTANDI® (enzalutamide capsules) is indicated for the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR). 

XTANDI is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). 

XTANDI is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). XTANDI has not been studied in patients with nmCRPC at low risk of developing metastatic disease. The benefit and risk profile in these patients is unknown. 

XTANDI is indicated in the setting of medical or surgical castration for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who: 

• are chemotherapy-naïve with asymptomatic or mildly symptomatic disease after failure of androgen deprivation therapy. 

• have received docetaxel therapy. 

Please consult the product monograph or call Medical Information at 1‑888‑338‑1824 for important information relating to: 

• Contraindications in women who are or may become pregnant, or who are lactating 

• The most serious warnings and precautions regarding seizures and Posterior Reversible Encephalopathy Syndrome (PRES) 

• Other relevant warnings and precautions regarding hereditary fructose intolerance, cytochrome P450 interactions and dose adjustments, carcinogenic potential, cardiovascular events (including ischemic heart disease, QTc prolongation and hypertension), hypersensitivity reactions, non-pathological bone fractures or falls and fall-related injuries, neuropsychiatric adverse events, mental impairment disorders, use of contraception, potential effects on male fertility, recommendations in severe renal impairment or end-stage renal disease and monitoring in nmCSPC with high-risk BCR or nmCRPC patients 

• Conditions of clinical use, adverse reactions, interactions and dosing